BlueSky Immunotherapies GmbH

A clinical study of an immunotherapy in patients with head or neck cancers associated with the HPV16 virus

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

This is a follow-up study for patients treated with FluBHPVE6E7 in previous interventional studies.